Stifel raised the firm’s price target on Ideaya Biosciences to $63 from $55 and keeps a Buy rating on the shares after new neoadjuvant data for darovasertib monotherapy were presented at ASCO and the company also reported on the first eight patients from the company-sponsored Phase 2 study. Based on the IST update, and the early window into the company’s Phase 2 trial, the firm is increasing its view on the odds of success to 55% from 40%, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces results from darovasertib trial
- Ideaya Biosciences names Daniel Simon chief business officer
- Ideaya Biosciences price target lowered to $55 from $57 at JPMorgan
- Ideaya Biosciences reports Q1 EPS (53c), consensus (51c)
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update